{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:28:25Z","timestamp":1794590905502,"version":"4.9.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Society for Haematology and Medical Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00277-017-3196-2","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T06:07:17Z","timestamp":1512626837000},"page":"197-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":177,"title":["Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-2503","authenticated-orcid":false,"given":"Sibylle C.","family":"Mellinghoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nael","family":"Alakel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Behre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Buchheidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Christopeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kiehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koldehoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lehners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika Y.","family":"L\u00f6hnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Maschmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Ullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-H.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"key":"3196_CR1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","volume":"56","author":"BD Alexander","year":"2013","unstructured":"Alexander BD, Johnson MD, Pfeiffer CD et al (2013) Increasing echinocandin resistance in Candida Glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724\u20131732","journal-title":"Clin Infect Dis"},{"key":"3196_CR2","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/AAC.00155-13","volume":"57","author":"L Annino","year":"2013","unstructured":"Annino L, Chierichini A, Anaclerico B et al (2013) Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob Agents Chemother 57:2596\u20132602","journal-title":"Antimicrob Agents Chemother"},{"key":"3196_CR3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00103-010-1028-9","volume":"53","author":"Anonymous","year":"2010","unstructured":"Anonymous (2010) Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch institute (RKI). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 53:357\u2013388","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"key":"3196_CR4","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee HR, Barnes RA, Johnson EM et al (2014) Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69:1162\u20131176","journal-title":"J Antimicrob Chemother"},{"key":"3196_CR5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D (2011) Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 29:532\u2013543","journal-title":"J Clin Oncol"},{"key":"3196_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00277-013-1854-6","volume":"93","author":"H Bertz","year":"2014","unstructured":"Bertz H, Drognitz K, Lubbert M (2014) No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year \"real-life\" evaluation. Ann Hematol 93:165\u2013167","journal-title":"Ann Hematol"},{"key":"3196_CR7","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465","journal-title":"N Engl J Med"},{"key":"3196_CR8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/dkp416","volume":"65","author":"RJ Bruggemann","year":"2010","unstructured":"Bruggemann RJ, Blijlevens NM, Burger DM et al (2010) Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 65:107\u2013113","journal-title":"J Antimicrob Chemother"},{"key":"3196_CR9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.05088-11","volume":"56","author":"SM Camps","year":"2012","unstructured":"Camps SM, Van Der Linden JW, Li Y et al (2012) Rapid induction of multiple resistance mechanisms in aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56:10\u201316","journal-title":"Antimicrob Agents Chemother"},{"key":"3196_CR10","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.01711-09","volume":"54","author":"M Castanheira","year":"2010","unstructured":"Castanheira M, Woosley LN, Diekema DJ et al (2010) Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother 54:2655\u20132659","journal-title":"Antimicrob Agents Chemother"},{"key":"3196_CR11","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","volume":"44","author":"MM Chau","year":"2014","unstructured":"Chau MM, Kong DC, Van Hal SJ et al (2014) Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J 44:1364\u20131388","journal-title":"Intern Med J"},{"key":"3196_CR12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2015.02.023","volume":"46","author":"GL Chong","year":"2015","unstructured":"Chong GL, Broekman F, Polinder S et al (2015) Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: efficacy and cost effectiveness in real-life. Int J Antimicrob Agents 46:82\u201387","journal-title":"Int J Antimicrob Agents"},{"key":"3196_CR13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"3196_CR14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","volume":"20","author":"OA Cornely","year":"2014","unstructured":"Cornely OA, Arikan-Akdagli S, Dannaoui E et al (2014) ESCMID\u2020 and ECMM\u2021 joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20:5\u201326","journal-title":"Clin Microbiol Infect"},{"key":"3196_CR15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","volume":"94","author":"OA Cornely","year":"2009","unstructured":"Cornely OA, Bohme A, Buchheidt D et al (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113\u2013122","journal-title":"Haematologica"},{"key":"3196_CR16","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","volume":"59","author":"OA Cornely","year":"2015","unstructured":"Cornely OA, Bohme A, Schmitt-Hoffmann A et al (2015) Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 59:2078\u20132085","journal-title":"Antimicrob Agents Chemother"},{"key":"3196_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12569","volume":"20","author":"OA Cornely","year":"2014","unstructured":"Cornely OA, Cuenca-Estrella M, Meis JF et al (2014) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) fungal infection study group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 20:1\u20134","journal-title":"Clin Microbiol Infect"},{"key":"3196_CR18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","volume":"71","author":"OA Cornely","year":"2016","unstructured":"Cornely OA, Duarte RF, Haider S et al (2016) Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother 71:718\u2013726","journal-title":"J Antimicrob Chemother"},{"key":"3196_CR19","doi-asserted-by":"crossref","unstructured":"CornelyOA, LeguayT, MaertensJet al. (2017) Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother","DOI":"10.1093\/jac\/dkx133"},{"key":"3196_CR20","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/jac\/dkx382","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely OA, Leguay T, Maertens J et al (2017) Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother 72:2359\u20132367","journal-title":"J Antimicrob Chemother"},{"key":"3196_CR21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: arandomized trial comparing a high\u2013loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289\u20131297","journal-title":"Clin Infect Dis"},{"key":"3196_CR22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348\u2013359","journal-title":"N Engl J Med"},{"key":"3196_CR23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/clpt.2010.261","volume":"89","author":"OA Cornely","year":"2011","unstructured":"Cornely OA, Ullmann AJ (2011) Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 89:351\u2013352","journal-title":"Clin Pharmacol Ther"},{"key":"3196_CR24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","volume":"57","author":"R Courtney","year":"2004","unstructured":"Courtney R, Wexler D, Radwanski E et al (2004) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57:218\u2013222","journal-title":"Br J Clin Pharmacol"},{"key":"3196_CR25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1188\/ONF.06.337-343","volume":"33","author":"D Demille","year":"2006","unstructured":"Demille D, Deming P, Lupinacci P et al (2006) The effect of the neutropenic diet in the outpatient setting: a pilot study. Oncol Nurs Forum 33:337\u2013343","journal-title":"Oncol Nurs Forum"},{"key":"3196_CR26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","volume":"34","author":"DW Denning","year":"2002","unstructured":"Denning DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563\u2013571","journal-title":"Clin Infect Dis"},{"key":"3196_CR27","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","volume":"58","author":"RF Duarte","year":"2014","unstructured":"Duarte RF, Lopez-Jimenez J, Cornely OA et al (2014) Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 58:5758\u20135765","journal-title":"Antimicrob Agents Chemother"},{"key":"3196_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","volume":"1508","author":"DA Enoch","year":"2017","unstructured":"Enoch DA, Yang H, Aliyu SH et al (2017) The changing epidemiology of invasive fungal infections. Methods Mol Biol (Clifton, N.J.) 1508:17\u201365","journal-title":"Methods Mol Biol (Clifton, N.J.)"},{"key":"3196_CR29","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","volume":"101","author":"S Faderl","year":"2003","unstructured":"Faderl S, Thomas DA, O'brien S et al (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413\u20133415","journal-title":"Blood"},{"key":"3196_CR30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clml.2013.09.014","volume":"14","author":"JF Falantes","year":"2014","unstructured":"Falantes JF, Calderon C, Marquez-Malaver FJ et al (2014) Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 14:80\u201386","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3196_CR31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/07357907.2016.1242009","volume":"34","author":"CA Garcia","year":"2016","unstructured":"Garcia CA, Wu S (2016) Attributable risk of infection to mTOR inhibitors Everolimus and Temsirolimus in the treatment of cancer. Cancer Investig 34:521\u2013530","journal-title":"Cancer Investig"},{"key":"3196_CR32","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/ofid\/ofv133.926","volume":"2","author":"MDC Garcia","year":"2015","unstructured":"Garcia MDC, Redelman-Sidi G (2015) Opportunistic infections in patients receiving immunotherapy with CTLA-4, PD-1 and PD-L1 blockers for treatment of metastatic melanoma. Open Forum Infect Dis 2:1214\u20131214","journal-title":"Open Forum Infect Dis"},{"key":"3196_CR33","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1200\/JCO.2008.16.4681","volume":"26","author":"A Gardner","year":"2008","unstructured":"Gardner A, Mattiuzzi G, Faderl S et al (2008) Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 26:5684\u20135688","journal-title":"J Clin Oncol"},{"key":"3196_CR34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1439-0507.1999.00518.x","volume":"42","author":"A Glasmacher","year":"1999","unstructured":"Glasmacher A, Hahn C, Molitor E et al (1999) Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42:591\u2013600","journal-title":"Mycoses"},{"key":"3196_CR35","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.01527-13","volume":"58","author":"MZ Gomes","year":"2014","unstructured":"Gomes MZ, Jiang Y, Mulanovich VE et al (2014) Effectiveness of primary anti-aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrob Agents Chemother 58:2775\u20132780","journal-title":"Antimicrob Agents Chemother"},{"key":"3196_CR36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/phar.1328","volume":"33","author":"BN Gross","year":"2013","unstructured":"Gross BN, Ihorst G, Jung M et al (2013) Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy 33:1117\u20131125","journal-title":"Pharmacotherapy"},{"key":"3196_CR37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/mmy\/myv099","volume":"54","author":"J Guinea","year":"2016","unstructured":"Guinea J, Escribano P, Marcos-Zambrano LJ et al (2016) Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels. Med Mycol 54:353\u2013360","journal-title":"Med Mycol"},{"key":"3196_CR38","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121\u20133127","journal-title":"J Clin Oncol"},{"key":"3196_CR39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","volume":"50","author":"R Hachem","year":"2017","unstructured":"Hachem R, Assaf A, Numan Y et al (2017) Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Int J Antimicrob Agents 50:384\u2013388","journal-title":"Int J Antimicrob Agents"},{"key":"3196_CR40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","volume":"19","author":"Y Hamada","year":"2013","unstructured":"Hamada Y, Tokimatsu I, Mikamo H et al (2013) Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 19:381\u2013392","journal-title":"J Infect Chemother"},{"key":"3196_CR41","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Brossart P, Wolf D (2013) Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122:3843\u20133844","journal-title":"Blood"},{"key":"3196_CR42","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SE, Daecke SN et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122:1192\u20131202","journal-title":"Blood"},{"key":"3196_CR43","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","volume":"96","author":"WJ Heinz","year":"2017","unstructured":"Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96:1775\u20131792","journal-title":"Ann Hematol"},{"key":"3196_CR44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408\u2013415","journal-title":"N Engl J Med"},{"key":"3196_CR45","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","volume":"15","author":"SJ Howard","year":"2009","unstructured":"Howard SJ, Cerar D, Anderson MJ et al (2009) Frequency and evolution of azole resistance in aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15:1068\u20131076","journal-title":"Emerg Infect Dis"},{"key":"3196_CR46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4149\/neo_2013_042","volume":"60","author":"R Hu","year":"2013","unstructured":"Hu R, Jiang X, Wu Y (2013) Prospective trial finds nystatin mouthwash effective prophylaxis for pulmonary invasive fungal infections that originate in the throat of patients with hematologic malignancies. Neoplasma 60:315\u2013321","journal-title":"Neoplasma"},{"key":"3196_CR47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1592\/phco.31.2.214","volume":"31","author":"T Hussaini","year":"2011","unstructured":"Hussaini T, Ruping MJ, Farowski F et al (2011) Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 31:214\u2013225","journal-title":"Pharmacotherapy"},{"key":"3196_CR48","first-page":"739","volume":"136","author":"A Imhof","year":"2006","unstructured":"Imhof A, Schaer DJ, Schanz U et al (2006) Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 136:739\u2013742","journal-title":"Swiss Med Wkly"},{"key":"3196_CR49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","volume":"88","author":"SH Jang","year":"2010","unstructured":"Jang SH, Colangelo PM, Gobburu JV (2010) Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 88:115\u2013119","journal-title":"Clin Pharmacol Ther"},{"key":"3196_CR50","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","volume":"36","author":"LB Johnson","year":"2003","unstructured":"Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630\u2013637","journal-title":"Clin Infect Dis"},{"key":"3196_CR51","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554\u20133561","journal-title":"Blood"},{"key":"3196_CR52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10096-016-2780-z","volume":"36","author":"CL Keighley","year":"2017","unstructured":"Keighley CL, Manii P, Larsen SR et al (2017) Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era. Eur J Clin Microbiol Infect Dis 36:213\u2013217","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3196_CR53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijantimicag.2016.10.019","volume":"49","author":"P Koehler","year":"2017","unstructured":"Koehler P, Hamprecht A, Bader O et al (2017) Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA study. Int J Antimicrob Agents 49:218\u2013223","journal-title":"Int J Antimicrob Agents"},{"key":"3196_CR54","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2010","unstructured":"Kontoyiannis DP, Marr KA, Park BJ et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis 50:1091\u20131100","journal-title":"Clin Infect Dis"},{"key":"3196_CR55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/152581603322023034","volume":"12","author":"WH Kruger","year":"2003","unstructured":"Kruger WH, Zollner B, Kaulfers PM et al (2003) Effective protection of allogeneic stem cell recipients against aspergillosis by HEPA air filtration during a period of construction--a prospective survey. J Hematother Stem Cell Res 12:301\u2013307","journal-title":"J Hematother Stem Cell Res"},{"key":"3196_CR56","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","volume":"369","author":"E-R Kuse","year":"2007","unstructured":"Kuse E-R, Chetchotisakd P, Da Cunha CA et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519\u20131527","journal-title":"Lancet"},{"key":"3196_CR57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-1426-2-19","volume":"2","author":"C Kyi","year":"2014","unstructured":"Kyi C, Hellmann MD, Wolchok JD et al (2014) Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2:19","journal-title":"J Immunother Cancer"},{"key":"3196_CR58","unstructured":"Lafon-DesmursB, MonselG, LeblondVet al.Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia. M\u00e9decine et Maladies Infectieuses"},{"key":"3196_CR59","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1270\u20131271","journal-title":"N Engl J Med"},{"key":"3196_CR60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1155\/2014\/340586","volume":"25","author":"M Laverdiere","year":"2014","unstructured":"Laverdiere M, Bow EJ, Rotstein C et al (2014) Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol 25:327\u2013343","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"3196_CR61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00277-006-0191-4","volume":"86","author":"P-C Lin","year":"2007","unstructured":"Lin P-C, Hsiao L-T, Poh S-B et al (2007) Higher fungal infection rate in elderly patients (more than 80years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol 86:95\u2013100","journal-title":"Ann Hematol"},{"key":"3196_CR62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/14787210.2017.1305886","volume":"15","author":"DI Marks","year":"2017","unstructured":"Marks DI, Liu Q, Slavin M (2017) Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation. Expert Rev Anti-Infect Ther 15:493\u2013502","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"Suppl 1","key":"3196_CR63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijantimicag.2006.03.006","volume":"27","author":"G Maschmeyer","year":"2006","unstructured":"Maschmeyer G (2006) The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents 27(Suppl 1):3\u20136","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"3196_CR64","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/jac\/dkp084","volume":"63","author":"G Maschmeyer","year":"2009","unstructured":"Maschmeyer G (2009) The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections. J Antimicrob Chemother 63(Suppl 1):i27\u2013i30","journal-title":"J Antimicrob Chemother"},{"key":"3196_CR65","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","volume":"67","author":"G Maschmeyer","year":"2007","unstructured":"Maschmeyer G, Haas A, Cornely OA (2007) Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67:1567\u20131601","journal-title":"Drugs"},{"key":"3196_CR66","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/annonc\/mdp034","volume":"20","author":"G Maschmeyer","year":"2009","unstructured":"Maschmeyer G, Neuburger S, Fritz L et al (2009) A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol 20:1560\u20131564","journal-title":"Ann Oncol"},{"key":"3196_CR67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1590\/0037-8682-0022-2013","volume":"46","author":"MG Menegueti","year":"2013","unstructured":"Menegueti MG, Ferreira LR, Silva MF et al (2013) Assessment of microbiological air quality in hemato-oncology units and its relationship with the occurrence of invasive fungal infections: an integrative review. Rev Soc Bras Med Trop 46:391\u2013396","journal-title":"Rev Soc Bras Med Trop"},{"key":"3196_CR68","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ajh.23368","volume":"88","author":"D Merkel","year":"2013","unstructured":"Merkel D, Filanovsky K, Gafter-Gvili A et al (2013) Predicting infections in high-risk patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol 88:130\u2013134","journal-title":"Am J Hematol"},{"key":"3196_CR69","doi-asserted-by":"crossref","unstructured":"MoodyKM, BakerRA, SantizoROet al. (2017) A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients. Pediatric Blood Cancer","DOI":"10.1002\/pbc.26711"},{"key":"3196_CR70","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/bmt.2016.256","volume":"51","author":"Y Mori","year":"2016","unstructured":"Mori Y, Ikeda K, Inomata T et al (2016) Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplant 51:1584\u20131587","journal-title":"Bone Marrow Transplant"},{"key":"3196_CR71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","volume":"23","author":"VA Morrison","year":"2010","unstructured":"Morrison VA (2010) Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol 23:145\u2013153","journal-title":"Best Pract Res Clin Haematol"},{"key":"3196_CR72","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116:4256\u20134265","journal-title":"Cancer"},{"key":"3196_CR73","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ejh.12426","volume":"94","author":"D Nachbaur","year":"2015","unstructured":"Nachbaur D, Angelova O, Orth-Holler D et al (2015) Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study. Eur J Haematol 94:258\u2013264","journal-title":"Eur J Haematol"},{"key":"3196_CR74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.riam.2009.04.001","volume":"26","author":"WL Nedel","year":"2009","unstructured":"Nedel WL, Kontoyiannis DP, Pasqualotto AC (2009) Aspergillosis in patients treated with monoclonal antibodies. Revista Iberoamericana de Micologia 26:175\u2013183","journal-title":"Revista Iberoamericana de Micologia"},{"key":"3196_CR75","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00277-013-1698-0","volume":"92","author":"S Neumann","year":"2013","unstructured":"Neumann S, Krause SW, Maschmeyer G et al (2013) Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors. Ann Hematol 92:433\u2013442","journal-title":"Ann Hematol"},{"key":"3196_CR76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bmt.1705749","volume":"40","author":"A Nihtinen","year":"2007","unstructured":"Nihtinen A, Anttila VJ, Richardson M et al (2007) The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. Bone Marrow Transplant 40:457\u2013460","journal-title":"Bone Marrow Transplant"},{"key":"3196_CR77","first-page":"4642831","volume":"2016","author":"K Okamoto","year":"2016","unstructured":"Okamoto K, Proia LA, Demarais PL (2016) Disseminated Cryptococcal disease in a patient with chronic lymphocytic leukemia on Ibrutinib. Case Rep Infect Dis 2016:4642831","journal-title":"Case Rep Infect Dis"},{"key":"3196_CR78","first-page":"1068","volume":"91","author":"L Pagano","year":"2006","unstructured":"Pagano L, Caira M, Candoni A et al (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068\u20131075","journal-title":"Haematologica"},{"key":"3196_CR79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","volume":"46","author":"A Pascual","year":"2008","unstructured":"Pascual A, Calandra T, Bolay S et al (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201\u2013211","journal-title":"Clin Infect Dis"},{"key":"3196_CR80","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/JCM.06112-11","volume":"50","author":"MA Pfaller","year":"2012","unstructured":"Pfaller MA, Castanheira M, Lockhart SR et al (2012) Frequency of decreased susceptibility and resistance to Echinocandins among fluconazole-resistant bloodstream isolates of Candida Glabrata. J Clin Microbiol 50:1199\u20131203","journal-title":"J Clin Microbiol"},{"key":"3196_CR81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","volume":"20","author":"MA Pfaller","year":"2007","unstructured":"Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133\u2013163","journal-title":"Clin Microbiol Rev"},{"key":"3196_CR82","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/myc.12500","volume":"59","author":"H Pomares","year":"2016","unstructured":"Pomares H, Arnan M, Sanchez-Ortega I et al (2016) Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses 59:516\u2013519","journal-title":"Mycoses"},{"key":"3196_CR83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/501967","volume":"23","author":"I Raad","year":"2015","unstructured":"Raad I, Hanna H, Osting C et al (2015) Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect Control Hospital Epidemiol 23:41\u201343","journal-title":"Infect Control Hospital Epidemiol"},{"key":"3196_CR84","first-page":"55","volume":"10","author":"M Reinwald","year":"2015","unstructured":"Reinwald M, Boch T, Hofmann WK et al (2015) Risk of infectious complications in Hemato-oncological patients treated with kinase inhibitors. Biomark Insights 10:55\u201368","journal-title":"Biomark Insights"},{"key":"3196_CR85","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2147\/OTT.S70524","volume":"8","author":"J-M Ribera","year":"2015","unstructured":"Ribera J-M, Ferrer A, Ribera J et al (2015) Profile of blinatumomab and its potential in the treatment of relapsed\/refractory acute lymphoblastic leukemia. OncoTargets Therapy 8:1567\u20131574","journal-title":"OncoTargets Therapy"},{"key":"3196_CR86","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1439-0507.2012.02193.x","volume":"55","author":"CT Rieger","year":"2012","unstructured":"Rieger CT, Cornely OA, Hoppe-Tichy T et al (2012) Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals. Mycoses 55:514\u2013520","journal-title":"Mycoses"},{"key":"3196_CR87","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","volume":"46","author":"BJ Rijnders","year":"2008","unstructured":"Rijnders BJ, Cornelissen JJ, Slobbe L et al (2008) Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: arandomized, placebo-controlled trial. Clin Infect Dis 46:1401\u20131408","journal-title":"Clin Infect Dis"},{"key":"3196_CR88","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1158\/1078-0432.CCR-10-1453","volume":"16","author":"JN Sarkaria","year":"2010","unstructured":"Sarkaria JN, Galanis E, Wu W et al (2010) Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 16:5573\u20135580","journal-title":"Clin Cancer Res"},{"key":"3196_CR89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13756-016-0132-5","volume":"5","author":"S Schelenz","year":"2016","unstructured":"Schelenz S, Hagen F, Rhodes JL et al (2016) First hospital outbreak of the globally emerging Candida Auris in a European hospital. Antimicrob Resist Infect Control 5:35","journal-title":"Antimicrob Resist Infect Control"},{"key":"3196_CR90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(08)70284-6","volume":"9","author":"A Schlesinger","year":"2009","unstructured":"Schlesinger A, Paul M, Gafter-Gvili A et al (2009) Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infect Dis 9:97\u2013107","journal-title":"Lancet Infect Dis"},{"key":"3196_CR91","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","volume":"75","author":"K Sch\u00f6nberg","year":"2015","unstructured":"Sch\u00f6nberg K, Rudolph J, Vonnahme M et al (2015) JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 75:2187\u20132199","journal-title":"Cancer Res"},{"key":"3196_CR92","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00432-015-1962-x","volume":"141","author":"KG Schrenk","year":"2015","unstructured":"Schrenk KG, Schnetzke U, Stegemann K et al (2015) Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. J Cancer Res Clin Oncol 141:1661\u20131668","journal-title":"J Cancer Res Clin Oncol"},{"key":"3196_CR93","first-page":"391","volume":"72","author":"S Scodavolpe","year":"2014","unstructured":"Scodavolpe S, Quaranta S, Lacarelle B et al (2014) Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization. Ann Biol Clin 72:391\u2013404","journal-title":"Ann Biol Clin"},{"key":"3196_CR94","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","volume":"72","author":"KE Stott","year":"2017","unstructured":"Stott KE, Hope WW (2017) Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemother 72:i12\u2013i18","journal-title":"J Antimicrob Chemother"},{"key":"3196_CR95","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-014-2108-y","volume":"93","author":"D Tacke","year":"2014","unstructured":"Tacke D, Buchheidt D, Karthaus M et al (2014) Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the infectious diseases working Party of the German Society for Haematology and oncology. Ann Hematol 93:1449\u20131456","journal-title":"Ann Hematol"},{"key":"3196_CR96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","volume":"46","author":"K Tan","year":"2006","unstructured":"Tan K, Brayshaw N, Tomaszewski K et al (2006) Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 46:235\u2013243","journal-title":"J Clin Pharmacol"},{"key":"3196_CR97","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.3324\/haematol.2015.126698","volume":"100","author":"JC Teng","year":"2015","unstructured":"Teng JC, Slavin MA, Teh BW et al (2015) Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica 100:e462\u2013e466","journal-title":"Haematologica"},{"key":"3196_CR98","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"3196_CR99","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10096-004-1103-y","volume":"23","author":"AM Tortorano","year":"2004","unstructured":"Tortorano AM, Peman J, Bernhardt H et al (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23:317\u2013322","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3196_CR100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","volume":"35","author":"S Trifilio","year":"2005","unstructured":"Trifilio S, Ortiz R, Pennick G et al (2005) Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35:509\u2013513","journal-title":"Bone Marrow Transplant"},{"key":"3196_CR101","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","volume":"109","author":"S Trifilio","year":"2007","unstructured":"Trifilio S, Pennick G, Pi J et al (2007) Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109:1532\u20131535","journal-title":"Cancer"},{"key":"3196_CR102","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","volume":"89","author":"K Ueda","year":"2009","unstructured":"Ueda K, Nannya Y, Kumano K et al (2009) Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 89:592\u2013599","journal-title":"Int J Hematol"},{"key":"3196_CR103","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335\u2013347","journal-title":"N Engl J Med"},{"key":"3196_CR104","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-016-2711-1","volume":"95","author":"AJ Ullmann","year":"2016","unstructured":"Ullmann AJ, Schmidt-Hieber M, Bertz H et al (2016) Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 95:1435\u20131455","journal-title":"Ann Hematol"},{"key":"3196_CR105","first-page":"Cd006247","volume":"4","author":"EC Dalen Van","year":"2016","unstructured":"Van Dalen EC, Mank A, Leclercq E et al (2016) Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev 4:Cd006247","journal-title":"Cochrane Database Syst Rev"},{"key":"3196_CR106","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","volume":"100","author":"LE Kolk Van Der","year":"2002","unstructured":"Van Der Kolk LE, Baars JW, Prins MH et al (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100:2257\u20132259","journal-title":"Blood"},{"key":"3196_CR107","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdm082","volume":"18","author":"FH Tiel Van","year":"2007","unstructured":"Van Tiel FH, Harbers MM, Terporten PHW et al (2007) Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematological malignancy: a study of safety\u2020. Ann Oncol 18:1080\u20131084","journal-title":"Ann Oncol"},{"key":"3196_CR108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","volume":"21-22","author":"PE Verweij","year":"2015","unstructured":"Verweij PE, Ananda-Rajah M, Andes D et al (2015) International expert opinion on the management of infection caused by azole-resistant aspergillus fumigatus. Drug Resist Updates 21-22:30\u201340","journal-title":"Drug Resist Updates"},{"key":"3196_CR109","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","volume":"348","author":"E Voog","year":"2003","unstructured":"Voog E, Morschhauser F, Solal-Celigny P (2003) Neutropenia in patients treated with rituximab. N Engl J Med 348:2691\u20132694 discussion 2691-2694","journal-title":"N Engl J Med"},{"key":"3196_CR110","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of Immune-Related Adverse Events and Kinetics of response with Ipilimumab. J Clin Oncol 30:2691\u20132697","journal-title":"J Clin Oncol"},{"key":"3196_CR111","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","volume":"116","author":"JR Wingard","year":"2010","unstructured":"Wingard JR, Carter SL, Walsh TJ et al (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116:5111\u20135118","journal-title":"Blood"},{"key":"3196_CR112","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijantimicag.2013.09.005","volume":"43","author":"H Wisplinghoff","year":"2014","unstructured":"Wisplinghoff H, Ebbers J, Geurtz L et al (2014) Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents 43:78\u201381","journal-title":"Int J Antimicrob Agents"},{"key":"3196_CR113","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","volume":"143","author":"NG Wysham","year":"2013","unstructured":"Wysham NG, Sullivan DR, Allada G (2013) An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 143:1478\u20131479","journal-title":"Chest"},{"key":"3196_CR114","doi-asserted-by":"crossref","first-page":"e94496","DOI":"10.1371\/journal.pone.0094496","volume":"9","author":"S Xie","year":"2014","unstructured":"Xie S, Chen M, Yan B et al (2014) Identification of a role for the PI3K\/AKT\/mTOR signaling pathway in innate immune cells. PLoS One 9:e94496","journal-title":"PLoS One"},{"key":"3196_CR115","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/588844","volume":"47","author":"DI Zonios","year":"2008","unstructured":"Zonios DI, Gea-Banacloche J, Childs R et al (2008) Hallucinations during voriconazole therapy. Clin Infect Dis 47:e7\u2013e10","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3196-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3196-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3196-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:42:44Z","timestamp":1660092164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3196-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3196"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3196-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}